ICU Medical (ICUI) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

ICU Medical

NasdaqGS•Healthcare•Medical Instruments & Supplies

$155.62-0.26(<0.01%)Pre-market

Market Cap

$3.82B

P/E

126.8x

P/S

1.8x

P/B

1.8x

ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications worldwide. It offers Clave needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoLock closed system transfer devices and ChemoClaveTM for preparation and administration of hazardous drugs; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; ClearGuard, SwabCap, and SwabTip disinfection caps; and vascular access products. The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride, sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. It offers infusion pumps under the Plum 360 and Plum Duo brands; ambulatory and syringe infusion hardware products; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform; LifeShield and PharmGuard medication infusion safety software; hemodynamic monitoring products; anesthesia systems and devices, breathing circuits, ventilation, respiratory, and specialty airway products; temperature management solutions; anesthesia/pain management trays and components; and professional services. The company's customers include acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, such as outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is based in San Clemente, California.

How this company scores

AverageMetricSide Score: 55/100

Strongest: Cash & Earnings Quality (16/25); weakest: Growth (11/25).

Profitability13/25

Growth11/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality16/25

Strengths

Rising free cash flowRising earningsProfit converts from growthImproving leverage

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 126.8x5y range 45.8x – 4878.3x

Currently near its 7-quarter median.

P/S · 1.8x5y range 1.1x – 3.9x

Currently near its 20-quarter median.

P/B · 1.8x5y range 1.1x – 3.1x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Earnings Quality

Red Flag

FCF consistently trails net income (avg -1.3x) — earnings may be inflated by non-cash items or aggressive accounting.

Revenue Decline

Watch

Revenue has softened, declining in 4 quarters. Watch for further erosion.

Price & Volume

Market Cap $3.82B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $2.16B
Q. Revenue: $551.68M
TTM EBITDA: $273.33M
TTM Op. Income: $72.06M
Q. Op. Income: $39.13M
TTM Net Income: $30.09M
Q. Net Income: $19.09M
EPS: $0.76
Shares Out.: $25.00M

$2.16B in TTM revenue declined 9.0% YoY, reaching $551.68M last quarter. TTM EBITDA of $273.33M and TTM operating income of $72.06M show growth is flowing through to the bottom line. TTM net income of $30.09M means revenue is converting into profit. Over the past year, TTM revenue is down 9% — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 42.6%
EBITDA Margin: 16.1%
Op. Margin: 7.1%
Net Margin: 3.5%

Op. margin of 7.1% is up 5.2% YoY — cost efficiency is improving. Net margin at 3.5% and gross margin of 42.6% show how much of each revenue dollar survives to profit. Across the last 8 quarters, operating margin has risen for 2 consecutive quarters — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 126.8x
P/S Ratio: 1.8x
P/B Ratio: 1.8x

At 126.8x P/E, the stock trades above typical market levels — the market expects above-average growth. P/S of 1.8x and P/B of 1.8x provide additional context. P/E sits above typical market levels while revenue growth is below 5%. Over the past year, P/E is up 0% — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $3.97B
Cash: $298.30M
Long-Term Debt: $1.21B
Book Value: $2.15B
D/E Ratio: 0.6
Debt/EBITDA: 13.7

With $3.97B in assets and $1.21B in long-term debt, D/E is 0.6and book value is $2.15B — a conservative capital structure with a cushion to weather downturns. Over the past year, debt/equity is down 11% — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $80.15M
TTM Free Cash Flow: $152.83M
FCF Margin: 7.1%
FCF / Net Income: 5.1

TTM FCF of $152.83M on $80.15M in operating cash flow. The FCF / Net Income ratio of 5.1x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is up 153% — an improving trend.